There are 2789 resources available
1023P - A novel microbiome-derived peptide, SG-3-00802 reverses resistance to anti-programmed death protein-1 (PD-1) therapy
Presenter: Helena Kiefel
Session: ePoster Display
1025TiP - SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI)
Presenter: Aleix Prat
Session: ePoster Display
1026TiP - A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
Presenter: Mehmet Altan
Session: ePoster Display
1027TiP - A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer
Presenter: Erkut Borazanci
Session: ePoster Display
1028TiP - ARC-12: Phase I/Ib dose escalation and dose expansion study to evaluate the safety and tolerability of AB308 + zimberelimab (AB122) in advanced malignancies
Presenter: Justin Call
Session: ePoster Display
1201P - Real-world comparative effectiveness of 1L alectinib (ALC) vs crizotinib (CRZ) in patients (pts) with ALK+ advanced NSCLC with or without baseline CNS metastases (mets)
Presenter: Matthew Krebs
Session: ePoster Display
1202P - ALK-2016-CPHG: French cohort of advanced non-small cell lung cancer (aNSCLC) with ALK (ALK+) or ROS1 (ROS1+) gene rearrangement treated by crizotinib
Presenter: Didier Debieuvre
Session: ePoster Display
1203P - The analysis of ALK fusion variants in 4991 EGFR/MET mutation-negative non-squamous non-small cell lung carcinomas (NSCLCs)
Presenter: Evgeny Imyanitov
Session: ePoster Display
1204P - Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain
Presenter: Ana Laura Ortega Granados
Session: ePoster Display